Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
°æÇÇÀû °ü»ó µ¿¸Æ ÁßÀç¼ú ÈÄ °ü»ó µ¿¸Æ ½ÉÀå Áúȯ ȯÀÚ¸¦À§ÇÑ Tong-xin-luo ĸ½¶

Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention
Chen Mao, Jin-Qiu Yuan, Zu-Yao Yang, Vincent CH Chung, Ying Qin, Yafang Huang, Wilson Wai San Tam, Joey SW Kwong, Wei Xie, Jin-Ling Tang
21 May 2015
°ËÅä±×·ì : ½ÉÀå±×·ì(Heart Group)
ÄÚÅ©¶õ¸µÅ© :



°æÇÇ °ü»ó µ¿¸Æ ÁßÀç¼ú (PCI)Àº °ü»ó µ¿¸Æ ½ÉÀå Áúȯ (CHD)¿¡ ´ëÇÑ Ç¥ÁØ Ä¡·á¹ýÀÌ´Ù. PCI ÈÄ 6 °³¿ù¿¡ °ü°­ Á÷°æÀÌ 50 % °¨¼ÒÇÑ °ÍÀ¸·Î Á¤ÀÇµÈ Ç÷°üÇùÂøÀº Ç÷°ü Àç»ýÀÌ ÇÊ¿äÇÔÀ» ³ªÅ¸³½´Ù. ÀçÇ÷°üÇùÂøÀº PCIÀÇ ÁÖ¿ä ´ÜÁ¡À¸·Î ÀÔÁõµÇ¾ú´Ù. Tong-xin-luo´Â Áß±¹¿¡¼­ ³Î¸® »ç¿ëµÇ´Â PCI ÀÌÈÄ È¯ÀÚÀÇ ½ÉÇ÷°ü Áúȯ ¿¹¹æ Àü·« Áß ÇϳªÀÌÁö¸¸, È¿´É°ú ¾ÈÀü¼ºÀº ü°èÀûÀ¸·Î Æò°¡µÇÁö ¾Ê¾Ò´Ù.



CHD ȯÀÚ¿¡¼­ PCI ÈÄ ½ÉÇ÷°ü ÁúȯÀ» ¿¹¹æÇÏ´Â µ¥ ÀÖ¾î Tong-xin-luo ĸ½¶ÀÇ È¿´É°ú ¾ÈÀü¼ºÀ» ü°èÀûÀ¸·Î Æò°¡ÇÑ´Ù.



ÄÚÅ©¶õ ¶óÀ̺귯¸®ÀÇ Cochrane Central Register of Controlled Trials, MEDLINE (OVID), EMBASE (OVID) WanFang, Chinese Biomedical Database, Chinese Medical Current Contents ¹× China National Knowledge Infrastructure¸¦ ÃÊÆǺÎÅÍ 2014 ³â 6 ¿ù±îÁö °Ë»öÇß´Ù. ÁøÇàÁßÀÎ ½ÃÇè ¹× ¿¬±¸ ·¹Áö½ºÆ®¸® µîµµ °Ë»öÇß´Ù. ¾ð¾î¿¡ ÀÇÇÑ Á¦ÇÑÀº ¾ø¾ú´Ù.



PCI ÀÌÈÄ CHD ´ë»óÀÚÀÇ ¹«ÀÛÀ§ ´ëÁ¶ ÀÓ»ó½ÃÇèÀÌ Æ÷ÇԵǾú´Ù. ½ÃÇ豺ÀÇ ´ë»óÀÚ´Â ÃÖ¼Ò 3 °³¿ù µ¿¾È Tong-xin-luo ĸ½¶À» Åõ¿©Çß´Ù.



µÎ ¸íÀÇ ¿¬±¸ÀÚ°¡ µ¶¸³ÀûÀ¸·Î µ¥ÀÌÅ͸¦ ÃßÃâÇÏ°í ºñ¶Ô¸²ÀÇ À§ÇèÀ» Æò°¡Çß´Ù. ¸ðµç ÀÇ°ß ºÒÀÏÄ¡´Â Á¦ 3ÀÇ ¿¬±¸ÀÚ¿Í ³íÀÇÇÏ¿© ÇØ°áµÇ¾ú´Ù. ÁÖ¿ä °á°ú´Â Ç÷°ü Á¶¿µ Àç¹ß ¹× ºÎÀÛ¿ëÀ» Æ÷ÇÔÇÏ¿´´Ù; ÀÌÂ÷ °á°ú¿¡´Â ½É±Ù°æ»ö, ½ÉºÎÀü, Çù½ÉÁõ, ¸ðµç »ç¸Á·ü, ½ÉÇ÷°ü°è ¹®Á¦·Î ÀÎÇÑ »ç¸Á·ü, Ç÷°ü Àç»ý »ç¿ë, ȯÀÚ ¼ö¿ë¼º, »îÀÇ Áú ¹× ºñ¿ë È¿À²¼ºÀÌ Æ÷ÇԵǾú´Ù. ÀÌ ºÐ¼º µ¥ÀÌÅÍ´Â 95 % ½Å·Ú ±¸°£ (CI)À¸·Î À§Çè ºñÀ² (RR)·Î ÃøÁ¤µÇ¾ú´Ù.



1063¸íÀÌ Âü¿©ÇÑ 16°³ÀÇ ¿¬±¸°¡ È®ÀεǾú´Ù. 15°ÇÀÇ ¿¬±¸¿¡ ´ëÇÑ ºñ¶Ô¸²ÀÇ À§ÇèÀÌ ³ô¾Ò°í ºÎÁ¤È®¼º ¹× ÀáÀçÀû ÃâÆÇ ºñ¶Ô¸² (publication bias)°ú ÇÔ²² °á°ú¿¡ ´ëÇÑ ½Å·Ú¸¦ ³·Ãß¾ú´Ù. Tong-xin-luo°¡ Ç÷°ü ÀçÇùÂø·ü (RR 0.16, 95% CI 0.07~0.34), ½É±Ù°æ»ö ¹ß»ý·ü(RR 0.26, 95% CI 0.11~0.62), ½ÉºÎÀü ¹ß»ý·ü(RR 0.26, 95% CI 0.11~0.62), Ç÷°ü Àç»ý »ç¿ëÀ²(RR 0.26, 95% CI 0.15~0.45)À» ³·Ãß¾ú´Ù´Â ÁúÀÌ ³·Àº ±Ù°Å°¡ ÀÖ¾ú´Ù. ÃÑ »ç¸Á·ü (RR 0.38, 95 % CI 0.06~2.56), Çù½ÉÁõ (RR 0.24, 95 % CI 0.17~0.34) ¹× ½ÉÇ÷°ü »ç¸Á (RR 0.31, 95 % CI 0.08 ~1.12)¿¡ ´ëÇÑ Tong-xin- luoÀÇ È¿°ú¿¡ ´ëÇØ ¸Å¿ì ³·Àº Ç°ÁúÀÇ ±Ù°Å¸¦ ¾òÀ» ¼ö ÀÖ¾ú´Ù. ºÎÀÛ¿ëÀº °ÅÀÇ º¸°íµÇÁö ¾Ê¾ÒÀ¸¸ç ºÎÀÛ¿ë¿¡´Â À§Àå ¹ÝÀÀ°ú ±¸¿ªÁúÀÌ Æ÷ÇԵǾú´Ù.



±âÁ¸ÀÇ ¼­¾ç ÀÇÇп¡ Tong-xin-luo¸¦ Ãß°¡Çϸé PCI ÈÄ CHD ȯÀÚ¿¡¼­ ÀçÇùÂø ¹× ½ÉÇ÷°ü°è ÁúȯÀÇ Àç¹ßÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Ù. ±×·¯³ª µ¥ÀÌÅÍ´Â ÃâÆÇ ºñ¶Ô¸²°ú Æ÷ÇÔµÈ ¿¬±¸¿¡¼­ ºñ¶Ô¸² À§ÇèÀÌ ³ô±â ¶§¹®¿¡ Á¦ÇѵǾî ÀÖ´Ù. ÀÌ Ä¡·áÀÇ ÀáÀçÀû ¿µÇâÀ» Æò°¡Çϱâ À§Çؼ­´Â Ãß°¡ÀûÀÎ Áú³ôÀº ÀÓ»ó½ÃÇèÀÌ ÇÊ¿äÇÏ´Ù.

±³½ÅÀúÀÚ
Jin-Ling Tang
jltang@cuhk.edu.hk.
Division of Epidemiology, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China.